Dyslipidemia

Reading File

Finding Sources

Searching PubMed

"dyslipidemia"[MeSH Terms] AND "management"[MeSH Terms]

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive content from multiple authoritative sources. Let me compile the full answer.

Dyslipidemia

Definition

Dyslipidemia refers to any abnormality in serum lipid levels - elevated LDL cholesterol (LDL-C), elevated triglycerides (TG), low HDL cholesterol (HDL-C), or combinations thereof. There is an unequivocal relationship between dyslipidemia and risk for atherogenesis within the coronary, peripheral, renal, and cerebral vasculature. Dyslipoproteinemias develop in response to genetic and environmental factors and are modifiable through lifestyle change and pharmacologic intervention.

Pathophysiology

Serum VLDL and LDL particles deliver cholesterol and triglycerides to peripheral tissues and blood vessel walls. These lipoproteins can cross the endothelial barrier and induce atherogenesis. Atherogenic lipoproteins not taken up by peripheral tissues are cleared from circulation by hepatic LDL receptors. Lipid-lowering therapies that upregulate hepatic LDL receptors are antiatherogenic by reducing circulating levels of these particles.

Dyslipidemia can result from abnormalities in:

Gastrointestinal nutrient absorption
Serum and intracellular enzyme activity (e.g., LPL, HMG-CoA reductase)
Cell surface receptor expression (e.g., LDL receptor mutations)

Classification

Primary (Genetic) Dyslipidemias

Severe Monogenic Dyslipidemias (from Fuster and Hurst's The Heart, 15th Ed):

Primary Lipid Disturbance	Disease	Inheritance	Causative Gene
Elevated LDL-C	Familial Hypercholesterolemia	Codominant	LDLR, APOB, PCSK9
Elevated LDL-C (recessive)	FH recessive form	Recessive	LDLRAP1
Elevated TG	Familial chylomicronemia	Recessive	LPL, APOC2, APOA5, LMF1, GPIHBP1

Key polygenic determinants of LDL-C include variants in APOE, LDLR, SORT1, APOB, ABCG5/8, and PCSK9 - each contributing 1-7 mg/dL per allele.

Hypercholesterolemia classification (based on LDL-C level and genetic mutation status):

LDL-C ≥190 mg/dL + pathogenic variant = Heterozygous FH
LDL-C ≥190 mg/dL + no mutation = Severe hypercholesterolemia
LDL-C normal + pathogenic variant = At-risk patient
Neither = Normal/polygenic

Secondary Dyslipidemias

Secondary causes must be ruled out and investigated as follows:

Secondary Cause	Investigations
Hypothyroidism	TSH
Diabetes / Insulin resistance	Fasting glucose, HbA1c, insulin/C-peptide
Chronic renal failure	Creatinine, urea
Nephrotic syndrome	Urinalysis, 24-hr urine albumin
Obstructive liver disease	AST, ALT, total bilirubin, ALP

Other secondary causes include obesity, metabolic syndrome, excess alcohol, and certain drugs (e.g., corticosteroids, thiazides, beta-blockers, HIV antiretroviral therapy - particularly protease inhibitors).

Diagnosis / Screening

A complete fasting lipid profile (12-14 hours) should be obtained, including:

LDL-C
Triglycerides
HDL-C
Total cholesterol (limited clinical relevance alone)

Because of the relationship between specific lipoprotein fractions and CAD risk, measuring total cholesterol alone has little clinical relevance.

Risk Assessment

The ACC/AHA Guideline on the Treatment of Blood Cholesterol has replaced the NCEP ATPIII recommendations and shifted to a risk-centric model:

Treatment decisions are based on overall ASCVD risk, not LDL-C targets alone
The Pooled Cohort Equation estimates 10-year ASCVD risk (includes ACS, MI, stable/unstable angina, coronary or arterial revascularization, stroke, TIA, PAD)
Threshold for initiating statin therapy in primary prevention: 10-year risk ≥7.5%

Risk-enhancing factors that may tip the decision toward treatment:

LDL-C ≥160 mg/dL or evidence of genetic hyperlipidemia
Family history of premature ASCVD (males <55 yr, females <65 yr in first-degree relatives)
High-sensitivity CRP >2 mg/L
Coronary artery calcium (CAC) score ≥300 Agatston units or ≥75th percentile for age/sex
Ankle-brachial index <0.9

Management

1. Therapeutic Lifestyle Changes (First-Line for All)

Therapeutic lifestyle change is first-line therapy for any patient at cardiovascular risk:

Dietary Component	Recommendation
Total fat	25%-35% of total calories
Saturated fat	Minimize; replaced with mono- and polyunsaturated fats
Polyunsaturated fat	≤10% of total calories
Monounsaturated fat	≤20% of total calories
Carbohydrate	50%-60% of total calories
Dietary fiber	20-30 g/day (viscous fiber reduces cholesterol absorption)
Dietary cholesterol	<200 mg/day
Exercise	20-30 min, 5x/week

Patients who smoke should stop. Plant stanols and sterols also reduce intestinal cholesterol absorption.

2. Statin Therapy (Cornerstone of Pharmacologic Treatment)

Statins are reversible, competitive HMG-CoA reductase inhibitors - blocking the rate-limiting step of cholesterol biosynthesis. They:

Upregulate hepatic LDL receptors, increasing clearance of atherogenic ApoB100-containing particles (VLDL, VLDL remnants, LDL)
Reduce VLDL secretion
Stimulate ApoA-I expression and hepatic HDL secretion
Slow and partially reverse atheromatous plaque progression

Intensity of statin therapy:

High-intensity: Reduces LDL-C by ≥50% (e.g., atorvastatin 40-80 mg, rosuvastatin 20-40 mg)
Moderate-intensity: Reduces LDL-C by 30-50%
Low-intensity: Reduces LDL-C by <30%

Indications (ACC/AHA):

Group	Recommendation
Clinical ASCVD (secondary prevention)	High-intensity statin (first line); moderate if high-intensity contraindicated
ASCVD + age >75 yr	Evaluate benefit/risk; continue if tolerating
Primary prevention: LDL-C ≥190 mg/dL	High-intensity statin (no 10-yr risk calc needed)
Primary prevention: 10-yr ASCVD ≥7.5%	Moderate-to-high intensity statin
Diabetes (age 40-75, LDL 70-189)	Moderate-intensity statin

Key adverse effects:

Myopathy / rhabdomyolysis (risk increased by CYP3A4 inhibitors, gemfibrozil interaction)
New-onset diabetes mellitus (~1 per 1,000 patients/year; higher at maximum doses); risk-benefit still favors treatment
Elevated transaminases (monitor LFTs)

Major clinical trials confirming benefit include: 4S, WOSCOPS, AFCAPS/TexCAPS, ASCOT, JUPITER, PROVE-IT, TNT.

3. Ezetimibe

Ezetimibe inhibits the Niemann-Pick C1-like 1 (NPC1L1) protein on the jejunal brush border, blocking intestinal cholesterol absorption. After glucuronidation it undergoes enterohepatic recirculation with negligible systemic exposure (half-life ~22 hours).

LDL-C reduction: ~20% (up to 25% in some patients)
Triglycerides: reduced up to 8%
HDL-C: raised up to 4%
Does NOT decrease absorption of bile acids, steroid hormones, or fat-soluble vitamins
Also approved for beta-sitosterolemia

Used as add-on to statin when LDL-C goals are not met on statin alone (IMPROVE-IT trial demonstrated incremental cardiovascular benefit).

4. PCSK9 Inhibitors

Monoclonal antibodies (evolocumab, alirocumab) that inhibit PCSK9, preventing degradation of LDL receptors and dramatically increasing LDL clearance. Used in:

Familial hypercholesterolemia (especially homozygous)
High-risk ASCVD patients not at goal on maximal statin + ezetimibe

5. Fibrates

Fibrate therapy (gemfibrozil, fenofibrate) is primarily indicated for:

Severe hypertriglyceridemia (TG ≥500 mg/dL) to reduce risk of pancreatitis
Mixed dyslipidemia

Key drug interaction: Gemfibrozil + statin combination significantly increases risk of myopathy (especially with cerivastatin - now withdrawn). Fenofibrate has a safer interaction profile with statins.

6. Niacin (Extended-Release)

Reduces TG and LDL-C; raises HDL-C
Mechanism: reduces hepatic VLDL synthesis
Adverse effects: flushing, hepatotoxicity, hyperglycemia
AIM-HIGH trial showed no additional cardiovascular benefit when added to statin therapy in patients with low HDL-C; clinical use has decreased significantly

7. Bile Acid Sequestrants

Colesevelam, cholestyramine, colestipol
Interrupt enterohepatic bile acid recirculation, increasing hepatic conversion of cholesterol to bile acids
LDL-C reduction: 15-30%
Safe in pregnancy
May raise triglycerides; avoid in hypertriglyceridemia

Special Populations

HIV/ART-associated dyslipidemia (from Braunwald's Heart Disease): HIV itself decreases total cholesterol, LDL-C, and HDL-C while raising TGs. ART (especially protease inhibitors like ritonavir) can cause extreme hypertriglyceridemia (>1000 mg/dL). INSTIs (raltegravir, dolutegravir) and maraviroc have more favorable lipid profiles.

Renal disease: Dyslipidemia is common in CKD and nephrotic syndrome; statin therapy is recommended for cardiovascular risk reduction.

Key Takeaways

Screen with a full fasting lipid panel; total cholesterol alone is insufficient
Rule out secondary causes before diagnosing primary dyslipidemia
Treatment decisions use ASCVD risk via the Pooled Cohort Equation, not LDL-C targets alone
Statins are the backbone of therapy - proven to reduce MI, stroke, and cardiovascular mortality
Ezetimibe adds incremental benefit when added to statins
PCSK9 inhibitors are reserved for high-risk patients or FH not at goal
Lifestyle modification (diet, exercise, smoking cessation) is first-line for all patients

Sources: Textbook of Family Medicine 9e, Ch. 27; Fuster and Hurst's The Heart, 15th Ed, Ch. 10; Braunwald's Heart Disease, 2-Vol Set

Tell me only what is sufficient for mbbs 1st year biochemistry exam question of 6 marks

Dyslipidemia – MBBS 1st Year Biochemistry (6 Marks)

Definition

Dyslipidemia is an abnormality in serum lipid levels characterized by:

Elevated LDL cholesterol
Elevated triglycerides
Decreased HDL cholesterol
Or a combination of the above

Classification

A. Primary (Genetic)

Due to inherited defects in lipoprotein metabolism.

Type	Defect	Lipid Abnormality
Familial Hypercholesterolemia	LDL receptor mutation	↑↑ LDL-C
Familial Hypertriglyceridemia	LPL or ApoC-II defect	↑↑ TG
Combined hyperlipidemia	Multiple gene defects	↑ LDL + ↑ TG

B. Secondary (Acquired)

Caused by underlying conditions:

Diabetes mellitus → ↑ VLDL, ↓ HDL
Hypothyroidism → ↑ LDL (reduced LDL receptor activity)
Nephrotic syndrome → ↑ LDL, ↑ TG
Obesity / Metabolic syndrome → ↑ TG, ↓ HDL
Drugs – corticosteroids, thiazides, beta-blockers

Biochemical Basis (Pathogenesis)

Cholesterol biosynthesis: Occurs in the liver via HMG-CoA reductase (rate-limiting enzyme)
LDL receptor pathway: LDL delivers cholesterol to cells via receptor-mediated endocytosis; defective receptors → ↑ circulating LDL
Reverse cholesterol transport: HDL carries cholesterol from peripheral tissues back to the liver (cardioprotective); reduced HDL → impaired reverse transport → atherogenesis
VLDL → IDL → LDL cascade: Excess VLDL (from high carb/fat intake or insulin resistance) leads to elevated LDL

Consequences

Atherosclerosis → Coronary artery disease, stroke
Acute pancreatitis (when TG >500 mg/dL)
Xanthomas and xanthelasmas (lipid deposits in skin/tendons)
Fatty liver

Management (Brief)

Approach	Example
Lifestyle	Low-fat diet, exercise, stop smoking
Statins	Inhibit HMG-CoA reductase → ↓ LDL synthesis
Fibrates	Activate PPAR-α → ↓ TG synthesis
Ezetimibe	Inhibit NPC1L1 → block intestinal cholesterol absorption
Niacin	↓ VLDL secretion, ↑ HDL

One-Line Exam Tips

Rate-limiting enzyme in cholesterol synthesis = HMG-CoA reductase (target of statins)
Most common cause of familial hypercholesterolemia = LDL receptor mutation
HDL is cardioprotective because it performs reverse cholesterol transport
TG >500 mg/dL = risk of acute pancreatitis

This is a shared conversation. Sign in to Orris to start your own chat.